Documentos clave

Ver Toda la documentación

M1000000

Methotrexate

Name: Methotrexate
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

(+)-Amethopterin, 4-Amino-10-methylfolic acid, 4-Amino-N¹⁰-methylpteroyl-L-glutamic acid, Antifolan, MTX, Methylaminopterin

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):

C₂₀H₂₂N₈O₅

Número CAS:

59-05-2

Peso molecular:

454.44

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329817845

MDL number:

MFCD00064370

Beilstein/REAXYS Number:

70669

Servicio técnico

¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.

Permítanos ayudarle

Propiedades

grade

pharmaceutical primary standard

API family

methotrexate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

InChI key

FBOZXECLQNJBKD-ZDUSSCGKSA-N

Gene Information

human ... DHFR(1719)

Descripción

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Methotrexate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under Methotrexate

pictograms

GHS06,GHS08

signalword

Danger

hcodes

H301,H341,H360D,H372

pcodes

P202 - P260 - P264 - P280 - P301 + P310 - P405

Hazard Classifications

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

target_organs

Liver,Bone marrow

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.

Joshua F Baker et al.

Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)

To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.

Anna-Birgitte Aga et al.

Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)

To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with

Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia.

E Driehuis et al.

PloS one, 15(5), e0231588-e0231588 (2020-05-19)

We have recently established a protocol to grow wildtype human oral mucosa organoids. These three-dimensional structures can be maintained in culture long-term, do not require immortalization, and recapitulate the multilayered composition of the epithelial lining of the oral mucosa. Here

Ver todos los artículos relacionados